Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Celcuity Inc. CELC
$9.59
-$0.14 (-1.44%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
212556120.00000000
-
week52high
14.40
-
week52low
4.81
-
Revenue
0
-
P/E TTM
-4
-
Beta
0.60000000
-
EPS
-2.56000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 20:00
Описание компании
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Needham | Buy | Buy | 17 мая 2022 г. |
| Canaccord Genuity | Buy | 08 окт 2021 г. | |
| Jefferies | Buy | 07 сент 2021 г. | |
| Cowen & Co. | Outperform | 29 июл 2021 г. | |
| Needham | Buy | 27 июл 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Buller Richard E | D | 9148 | 300 | 19 дек 2022 г. |
| Sullivan Brian F. | D | 0 | 260869 | 09 дек 2022 г. |
| Sullivan Brian F. | D | 104340 | 104340 | 09 дек 2022 г. |
| Sullivan Brian F. | D | 0 | 260869 | 09 дек 2022 г. |
| Sullivan Brian F. | A | 3016643 | 260869 | 09 дек 2022 г. |
| Furcht Leo | A | 0 | 250 | 29 ноя 2022 г. |
| Furcht Leo | A | 250 | 250 | 29 ноя 2022 г. |
| Murphy Polly A. | A | 5000 | 5000 | 22 ноя 2022 г. |
| Buller Richard E | D | 9448 | 300 | 20 окт 2022 г. |
| Murphy Polly A. | A | 16300 | 16300 | 12 сент 2022 г. |
Новостная лента
Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call
Accesswire
08 мая 2023 г. в 17:30
MINNEAPOLIS, MN / ACCESSWIRE / May 8, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2023 after the stock market close on Monday, May 15, 2023. Management will host a webcast/teleconference the same day at 4:30 p.m.
Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress
Accesswire
08 мая 2023 г. в 08:00
MINNEAPOLIS, MN / ACCESSWIRE / May 8, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced publication of an abstract reporting updated results for treatment-naïve patients from the Phase 1b study of gedatolisib, a pan-PI3K/mTOR inhibitor, in combination with palbociclib and letrozole in women with HR+/HER2- advanced breast cancer (ABC). A poster will be presented at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress, which is being held May 11-13, 2023 in Berlin, Germany.
Celcuity Inc. (CELC) Q4 2022 Earnings Call Transcript
Seeking Alpha
23 мар 2023 г. в 20:04
Celcuity Inc. (NASDAQ:CELC ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Robert Uhl - ICR Westwicke, IR Brian Sullivan - CEO and Co-Founder Vicky Hahne - CFO Igor Gorbatchevsky - Chief Medical Officer Conference Call Participants Maury Raycroft - Jefferies Alex Nowak - Craig-Hallum Operator Greetings. And welcome to Celcuity's Full Year 2022 Financial Results Conference Call.
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call
Accesswire
16 мар 2023 г. в 08:00
MINNEAPOLIS, MN / ACCESSWIRE / March 16, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2022 after the stock market close on Thursday, March 23, 2023. Management will host a webcast/teleconference the same day at 4:30 p.m.
Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
Accesswire
15 мар 2023 г. в 19:35
MINNEAPOLIS, MN / ACCESSWIRE / March 15, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced publication of an abstract reporting data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR inhibitors in endometrial, ovarian, and cervical cancer cell lines. A poster will be presented at the 2023 Annual Meeting of the American Association for Cancer Research (AACR), which will be held April 14-19, 2023 in Orlando, Florida.